A database of hospital discharge data from approximately 300,000 deliveries in the United States found the overall incidence of preeclampsia with severe features was approximately 1 percent of all pregnancies [ 2 ]. Studies limited to nulliparous women report that approximately 5 percent develop preeclampsia and 40 to 50 percent of these women develop features of severe disease [ 3,4 ]. The incidence of preeclampsia with severe features before 34 weeks is percent [ 5 ]. However, these figures were derived from studies using the pre-2013 definition of severe preeclampsia. (See 'Terminology' above.)
Perhaps the most notable movie scene involving menarche is that from the 1976 horror movie Carrie . Carrie White experiences her first period as she showers after the school gym class, and unaware of what is happening to her, she panics and pleads for help, but the other girls respond by bullying her. The movie is an adaptation of the novel with the same name by Stephen King . Carrie's first period unleashes her violent powers and is central to her dangerous and out of control transformation. This theme is common to horror movies, another notable example being the 2000 Canadian horror film Ginger Snaps , where the protagonist's first period is central to her gradual transformation into a werewolf . Girls experiencing their first period is part of many movies, though not central to their plot, including The Blue Lagoon , My Girl , A Walk on the Moon .
Recent data also suggest that betamethasone can be beneficial in pregnant women at high risk of late preterm birth, between 34 0/7 weeks and 36 6/7 weeks of gestation who have not received a prior course of antenatal corticosteroids. The Maternal Fetal Medicine Units (MFMU) Network Antenatal Late Preterm Steroids trial ( 24 ) was a double-blind, placebo-controlled, randomized clinical trial designed to evaluate the use of antenatal betamethasone for pregnant women at high risk of delivery in the late preterm period. Women were identified to be at high risk if they presented in preterm labor, had preterm PROM, or if they had a planned delivery in the late preterm period, with the indication at the discretion of the obstetrician–gynecologist or other health care provider. Tocolysis was not employed as a part of this trial, and delivery was not delayed for obstetric or medical indications. The study found that the administration of betamethasone led to a significant decrease in the primary outcome, which was the need for respiratory support. A larger decrease was demonstrated for severe respiratory complications, from % in the placebo group to % in the betamethasone group (RR, ; 95% CI, –; P <.001). There were also significant decreases in the rates of transient tachypnea of the newborn; bronchopulmonary dysplasia; a composite of respiratory distress syndrome (RDS), transient tachypnea of the newborn and RDS; and the need for postnatal surfactant. Infants exposed to betamethasone were less likely to require immediate postnatal resuscitation. There was no increase in proven neonatal sepsis, chorioamnionitis, or endometritis with late preterm betamethasone. Hypoglycemia was more common in the infants exposed to betamethasone % versus % (RR, ; 95% CI, –); however, there were no reported adverse events related to hypoglycemia, which was not associated with an increased length of hospital stay. The rates of hypoglycemia found in the trial are similar to what is reported in the general population of late preterm infants ( 25 ). Although not studied in this trial, long-term adverse outcomes of prolonged and persistent neonatal hypoglycemia have been described ( 26 , 27 ). In order to reduce this risk and achieve the benefits of betamethasone therapy for fetal maturity in late preterm pregnancies, the American Academy of Pediatrics’ guidelines should be followed when employing this therapy (27). The American Academy of Pediatrics recommends the monitoring of neonatal blood sugars for late preterm infants because late preterm birth is a known risk factor for hypoglycemia. A single course of betamethasone is recommended for pregnant women between 34 0/7 weeks and 36 6/7 weeks of gestation at risk of preterm birth within 7 days, and who have not received a previous course of antenatal corticosteroids (24, 28 ).